Somatic mutations in MYD88 and CXCR4 are determinants of clinical presentation and overall survival in Waldenström macroglobulinemia
Top Cited Papers
- 1 May 2014
- journal article
- Published by American Society of Hematology in Blood
- Vol. 123 (18), 2791-2796
- https://doi.org/10.1182/blood-2014-01-550905
Abstract
Key Points Activating MYD88 as well as nonsense and frameshift WHIM-like CXCR4 somatic mutations are common in WM. CXCR4 NS mutations are present in aggressive cases including hyperviscosity syndrome, and MYD88 status is a determinant of survival.Keywords
This publication has 18 references indexed in Scilit:
- MYD88 L265P Somatic Mutation in Waldenström's MacroglobulinemiaThe New England Journal of Medicine, 2012
- Clinical and Genetic Features of Warts, Hypogammaglobulinemia, Infections and Myelokathexis (WHIM) SyndromeCurrent Molecular Medicine, 2011
- Site-specific Phosphorylation of CXCR4 Is Dynamically Regulated by Multiple Kinases and Results in Differential Modulation of CXCR4 SignalingOnline Journal of Public Health Informatics, 2010
- SDF1/CXCL12 (−801GA) polymorphism is a prognostic factor after treatment initiation in Waldenstrom macroglobulinemiaLeukemia Research, 2009
- How I treat Waldenström macroglobulinemiaBlood, 2009
- Update on Treatment Recommendations From the Fourth International Workshop on Waldenström's MacroglobulinemiaJournal of Clinical Oncology, 2009
- SDF-1/CXCR4 and VLA-4 interaction regulates homing in Waldenstrom macroglobulinemiaBlood, 2008
- Regulation of CXCR4 signalingBiochimica et Biophysica Acta (BBA) - Biomembranes, 2007
- Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia: Consensus Panel Recommendations from the Second International Workshop on Waldenstrom's MacroglobulinemiaSeminars in Oncology, 2003
- Clinicopathological definition of Waldenstrom's macroglobulinemia: Consensus Panel Recommendations from the Second International Workshop on Waldenstrom's MacroglobulinemiaSeminars in Oncology, 2003